15 to 20 minutes presentation with 2026 news for routine approach of a SLE patient, focused on advanced therapies including sc anifrolumab; in am professor of rheumatology, audience - top specialists in rheumatology; english; maybe we can add from BRS 2026 Romanian oct 2026, EULAR and ACR updates data about monitoring, standard of care - please add rules for HCQ, GC, IS drugs; and if guidelines tell us about ANIFROLUMAB AND COMBINATION THERAPY; ADD MORE THAT 1- SLIDES . GO TO 20
15 to 20 minutes presentation with 2026 news for routine approach of a SLE patient, focused on advanced therapies including sc anifrolumab; in am professor of rheumatology, audience - top specialists in rheumatology; english; maybe we can add from BRS 2026 Romanian oct 2026, EULAR and ACR updates data about monitoring, standard of care - please add rules for HCQ, GC, IS drugs; and if guidelines tell us about ANIFROLUMAB AND COMBINATION THERAPY; ADD MORE THAT 1- SLIDES . GO TO 20
Created using ChatSlide
This document outlines the 2026 SLE Routine Assessment and Targets, emphasizing the definition of remission and treatment goals, organ screening, and activity monitoring. It details standard care practices, including the use of hydroxychloroquine, glucocorticoid minimization, and tailored immunosuppression. Additionally, it introduces advanced therapy options, such as subcutaneous anifrolumab for inadequate control, and highlights the importance of assessing combination therapies and...